{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:09:51Z","timestamp":1787026191285,"version":"build-2736575974"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Soon after the release of the new anti-COVID mRNA vaccines, reports came in from the US and the UK of anaphylactic reactions. Fueled by the necessary caution toward these new vaccine platforms, these reports had a great impact and were largely commented upon in the scientific literature and global media. The current estimated frequency is of 5 cases per million doses. Very little biological data are presented in the literature to support the anaphylaxis diagnosis in these patients in addition to skin tests. Allergic reactions to vaccines are rare and mostly due to vaccine excipient. Therefore, the poly-ethylene-glycol (PEG) present in both mRNA formulation, and already known to be immunogenic, was soon suspected to be the potential culprit. Several hypersensitivity mechanisms to PEG or to other vaccine components can be suspected, even if the classical IgE-dependent anaphylaxis seems to be one of the most plausible candidates. In the early 2022, the international guidelines recommended to perform skin prick tests and basophil activation tests (BAT) in people experiencing allergic reaction to the first dose of COVID-19 vaccine or with a history of PEG allergy. The aim of this review is to discuss the main potential mechanisms of immediate allergy to COVID19 vaccines based on published data, together with the various techniques used to confirm or not sensitization to one component.<\/jats:p>","DOI":"10.3389\/falgy.2022.1007602","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T02:24:26Z","timestamp":1664504666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis"],"prefix":"10.3389","volume":"3","author":[{"given":"Pascale","family":"Nicaise-Roland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Barbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chollet-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"de Chaisemartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/all.15241","article-title":"Allergies and COVID-19 vaccines: an ENDA\/EAACI position paper","volume":"77","author":"Barbaud","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1002\/hsr2.787","article-title":"Anaphylaxis and allergic reactions to COVID-19 vaccines: a narrative review of characteristics and potential obstacles on achieving herd immunity","volume":"5","author":"Mahdiabadi","year":"2022","journal-title":"Health Sci Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2021.02.013","article-title":"Mechanisms of human drug-induced anaphylaxis","volume":"147","author":"Bruhns","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/microorganisms10030624","article-title":"Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: a worldwide review","volume":"10","author":"Kroumpouzos","year":"2022","journal-title":"Microorganisms"},{"key":"B5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.jaip.2022.04.035","article-title":"Adverse events and safety of SARS-CoV-2 vaccines: what's new and what's next","volume":"10","author":"Corey","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1479","article-title":"An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis","volume":"11","author":"J\u00f6nsson","year":"2019","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1172\/JCI45232","article-title":"Mouse and human neutrophils induce anaphylaxis","volume":"121","author":"J\u00f6nsson","year":"2011","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2011-07-367334","article-title":"Human Fc\u03b3RIIA induces anaphylactic and allergic reactions","volume":"119","author":"J\u00f6nsson","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/IJN.S187139","article-title":"Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice","volume":"14","author":"\u0150rfi","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1021\/acsnano.0c03648","article-title":"Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines","volume":"14","author":"Gabizon","year":"2020","journal-title":"ACS Nano"},{"key":"B14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein\u2013coupled receptor X2 on mast cell\u2013mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1111\/all.14252","article-title":"Surface expression of MRGPRX2 on resting basophils: an area of controversy","volume":"75","author":"Sabato","year":"2020","journal-title":"Allergy."},{"key":"B16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/cea.14110","article-title":"Tryptase release does not discriminate between IgE- and MRGPRX2-mediated activation in human mast cells","volume":"52","author":"Elst","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/all.14722","article-title":"COVID-19 vaccine anaphylaxis: PEG or not?","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaip.2014.01.017","article-title":"Macrogol hypersensitivity reactions during cleansing preparation for colon endoscopy","volume":"2","author":"Pizzimenti","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children's Oncology group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr Blood Cancer. Mars"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jaip.2020.11.011","article-title":"Anti-PEG IgE in anaphylaxis associated with polyethylene glycol","volume":"9","author":"Zhou","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12111","DOI":"10.1002\/clt2.12111","article-title":"Allergy to polyethylene glycol and polysorbates in a patient cohort: diagnostic work-up and decision points for vaccination during the COVID-19 pandemic","volume":"12","author":"Mortz","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.3390\/ijms23168838","article-title":"Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration","volume":"23","author":"Guerrini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract. Juin"},{"key":"B26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"114079","DOI":"10.1016\/j.addr.2021.114079","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine's Most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv Drug Deliv Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/all.15187","article-title":"The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines","volume":"77","author":"Cabanillas","year":"2022","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaip.2018.08.035","article-title":"Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging","volume":"7","author":"Lukawska","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.tjem.2016.09.003","article-title":"Anaphylaxis after intravenous infusion of dexketoprofen trometamol","volume":"16","author":"Guler","year":"2016","journal-title":"Turk J Emerg Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.jaip.2019.05.058","article-title":"Polyethylene glycols and polysorbates: two still neglected ingredients causing true IgE-mediated reactions","volume":"7","author":"Calogiuri","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-Dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2125524","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of Pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","article-title":"Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma","volume":"8","author":"Fang","year":"2021","journal-title":"Toxicol Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"715844","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Front Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11095-013-1067-7","article-title":"The immunogenicity of polyethylene glycol: facts and fiction","volume":"30","author":"Schellekens","year":"2013","journal-title":"Pharm Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jaip.2022.04.006","article-title":"Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines","volume":"10","author":"Mathes","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.anai.2021.09.012","article-title":"Non-immunoglobulin E-mediated allergy associated with Pfizer-BioNTech coronavirus disease 2019 vaccine excipient polyethylene glycol","volume":"127","author":"Jiang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.vaccine.2020.12.084","article-title":"Anaphylactic reactions to novel mRNA SARS-CoV-2\/COVID-19 vaccines","volume":"39","author":"Kelso","year":"2021","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/vaccines9090974","article-title":"Pseudo-Anaphylactic reactions to pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis post pfizer BNT162b2 vaccination","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.anai.2021.11.012","article-title":"Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: not the usual suspects?","volume":"128","author":"de Chaisemartin","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/vaccines9050412","article-title":"Allergy to polyethilenglicole of anti-SARS CoV2 vaccine recipient: a case report of young adult recipient and the management of future exposure to SARS-CoV2","volume":"9","author":"Restivo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don\u2019t give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/all.15148","article-title":"The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine","volume":"77","author":"Labella","year":"2022","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.anai.2021.03.012","article-title":"Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report","volume":"126","author":"Pitlick","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.23822\/EurAnnACI.1764-1489.220","article-title":"Patients with elevated basal tryptase serum levels should be tested for hereditary alpha-tryptasemia","volume":"54","author":"Spoerl","year":"2022","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jaci.2019.07.037","article-title":"Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the anaphylaxis registry (NORA)","volume":"144","author":"D\u00f6lle-Bierke","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/all.15278","article-title":"Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?","author":"Eberlein","year":"2022","journal-title":"Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e12044","DOI":"10.1002\/clt2.12044","article-title":"Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up","volume":"11","author":"Rasmussen","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2021.05.020","article-title":"Optimizing investigation of suspected allergy to polyethylene glycols","volume":"149","author":"Bruusgaard-Mouritsen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2140364","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaci.2022.03.023","article-title":"Rapid progress in our understanding of COVID-19 vaccine allergy: a cause for optimism, not hesitancy","volume":"150","author":"Banerji","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/all.15414","article-title":"Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity","author":"Worm","year":"2022","journal-title":"Allergy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"825164","DOI":"10.3389\/falgy.2022.825164","article-title":"Successful desensitization to mRNA COVID-19 vaccine in a case series of patients with a history of anaphylaxis to the first vaccine dose","volume":"3","author":"AlMuhizi","year":"2022","journal-title":"Front Allergy"},{"key":"B58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat Nanotechnol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.1007602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T02:24:29Z","timestamp":1664504669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.1007602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":58,"alternative-id":["10.3389\/falgy.2022.1007602"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2022.1007602","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"1007602"}}